225 related articles for article (PubMed ID: 17313469)
21. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole: a new triazole antifungal agent.
Johnson LB; Kauffman CA
Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
[TBL] [Abstract][Full Text] [Related]
23. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
24. Fluorosis because of prolonged voriconazole therapy in a teenager with acute myelogenous leukemia.
Skiles JL; Imel EA; Christenson JC; Bell JE; Hulbert ML
J Clin Oncol; 2011 Nov; 29(32):e779-82. PubMed ID: 21969513
[No Abstract] [Full Text] [Related]
25. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole therapy in children with cystic fibrosis.
Hilliard T; Edwards S; Buchdahl R; Francis J; Rosenthal M; Balfour-Lynn I; Bush A; Davies J
J Cyst Fibros; 2005 Dec; 4(4):215-20. PubMed ID: 16243008
[TBL] [Abstract][Full Text] [Related]
27. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
28. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.
Otsuka M; Kanamori H; Sasaki S; Taguchi J; Harano H; Ogawa K; Matsuzaki M; Mohri H; Okubo T; Sumita S; Ochiai H
Intern Med; 1997 Oct; 36(10):705-8. PubMed ID: 9372331
[TBL] [Abstract][Full Text] [Related]
29. Adverse reactions to voriconazole.
Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
31. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
32. Painful peripheral neuropathy associated with voriconazole use.
Tsiodras S; Zafiropoulou R; Kanta E; Demponeras C; Karandreas N; Manesis EK
Arch Neurol; 2005 Jan; 62(1):144-6. PubMed ID: 15642862
[TBL] [Abstract][Full Text] [Related]
33. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
34. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
Amankwa K; Krishnan SC; Tisdale JE
Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
[TBL] [Abstract][Full Text] [Related]
35. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia.
Kishi S; Yoshida A; Yamauchi T; Tsutani H; Lee JD; Nakamura T; Naiki H; Ueda T
Int J Hematol; 2000 Feb; 71(2):172-9. PubMed ID: 10745628
[TBL] [Abstract][Full Text] [Related]
36. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
37. Voriconazole-associated myositis.
Shanmugam VK; Matsumoto C; Pien E; Rosen J; Kumar P; Whelton S; Steen V
J Clin Rheumatol; 2009 Oct; 15(7):350-3. PubMed ID: 20009971
[TBL] [Abstract][Full Text] [Related]
38. Moxifloxacin and torsade de pointes.
Dale KM; Lertsburapa K; Kluger J; White CM
Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
40. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
Klein KC; Blackwood RA
Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
